Clover Health Investments, Corp. (CLOV)
NASDAQ: CLOV · Real-Time Price · USD
2.640
+0.120 (4.76%)
At close: Apr 28, 2026, 4:00 PM EDT
2.630
-0.010 (-0.38%)
After-hours: Apr 28, 2026, 6:18 PM EDT
Clover Health Investments Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Clover Health Investments stock have an average target of 2.90, with a low estimate of 2.50 and a high estimate of 3.20. The average target predicts an increase of 9.85% from the current stock price of 2.64.
Analyst Consensus: Buy
* Price targets were last updated on Mar 20, 2026.
Analyst Ratings
The average analyst rating for Clover Health Investments stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 2 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $3.7 → $3.2 | Strong Buy | Maintains | $3.7 → $3.2 | +21.21% | Mar 20, 2026 |
| Leerink Partners | Leerink Partners | Hold Maintains $3 → $2.5 | Hold | Maintains | $3 → $2.5 | -5.30% | Mar 5, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $3.7 | Strong Buy | Maintains | $3.7 | +40.15% | Jan 20, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4.1 → $3.7 | Strong Buy | Maintains | $4.1 → $3.7 | +40.15% | Nov 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4.5 → $4.1 | Strong Buy | Maintains | $4.5 → $4.1 | +55.30% | Aug 7, 2025 |
Financial Forecast
Revenue This Year
2.94B
from 1.92B
Increased by 52.59%
Revenue Next Year
3.39B
from 2.94B
Increased by 15.37%
EPS This Year
-0.00
from -0.17
EPS Next Year
0.01
from -0.00
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3.0B | 3.6B | |||
| Avg | 2.9B | 3.4B | |||
| Low | 2.8B | 3.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 57.8% | 22.7% | |||
| Avg | 52.6% | 15.4% | |||
| Low | 45.9% | 7.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.01 | 0.04 | |||
| Avg | -0.00 | 0.01 | |||
| Low | -0.02 | -0.02 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.